Search | Clinical Trials Finder

Conditions: Sexual Dysfunctions, Psychological, Sexual Arousal Disorder
Interventions: sildenafil; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 82
States / cities: Huntsville, Alabama • Anchorage, Alaska • Tucson, Arizona + 68 more

Conditions: Prostatic Neoplasms
Interventions: Apalutamide, ADT, Relugolix; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 32
States / cities: Tucson, Arizona • Little Rock, Arkansas • Sherman Oaks, California + 28 more

Conditions: Adult Cystic Nephroma, Anaplastic Kidney Wilms Tumor, Angiolipoma, Cellular Congenital Mesoblastic Nephroma, Classic Congenital Mesoblastic Nephroma, Clear Cell Sarcoma of the Kidney, Congenital Mesoblastic Nephroma, Cystic Partially Differentiated Kidney Nephroblastoma, Diffuse Hyperplastic Perilobar Nephroblastomatosis, Extrarenal Rhabdoid Tumor, Kidney Medullary Carcinoma, Kidney Neoplasm, Kidney Oncocytoma, Kidney Wilms Tumor, Metanephric Adenofibroma, Metanephric Adenoma, Metanephric Stromal Tumor, Metanephric Tumor, Mixed Congenital Mesoblastic Nephroma, Ossifying Renal Tumor of Infancy, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions, Rhabdoid Tumor of the Kidney, Wilms Tumor
Interventions: Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 29 Years
Enrollment: 8,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2026
U.S. locations: 214
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more

Conditions: Exercise Induced Bronchospasm, Asthma
Interventions: Not listed
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Breast Cancer
Interventions: DS-8201a; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 36
States / cities: Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 26 more

Conditions: Hypertension, Pulmonary Artery, Ventricular Dysfunction, Left
Interventions: sildenafil; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Benign Prostatic Hyperplasia (BPH)
Interventions: Silodosin, Placebo; Drug · Other
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 43
States / cities: Huntsville, Alabama • Tucson, Arizona • Anaheim, California + 40 more

Conditions: Interstitial Cystitis, Bladder Pain Syndrome
Interventions: IW-3300 rectal foam, Placebo; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 53
States / cities: Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more

Conditions: Pain, Neuralgia, Postherpetic, Neuralgia, Mononeuropathies
Interventions: JNJ-42160443, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 40
States / cities: Tucson, Arizona • Fresno, California • Redondo Beach, California + 37 more

Conditions: Urinary Bladder, Overactive
Interventions: Mirabegron, Tolterodine, Placebo to Mirabegron, Placebo to Tolterodine; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 2,792 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 106
States / cities: Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 96 more

Conditions: Diabetes Mellitus, Non-Insulin-Dependent
Interventions: Glucovance (metformin HCl/glyburide), metformin HCl, glyburide; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 9 Years to 16 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 50
States / cities: Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 43 more

Conditions: Acute Ischemic Stroke, Diabetes, Hyperglycemia
Interventions: IV insulin to maintain target glucose concentration of 80-130 mg/dL, Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 1,151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 70
States / cities: Tucson, Arizona • Long Beach, California • Los Angeles, California + 45 more

Conditions: Influenza
Interventions: Vero cell-derived, trivalent, seasonal influenza vaccine, Placebo: Phosphate-buffered saline; Biological
Lead sponsor: Alachua Government Services, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 7,250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 36
States / cities: Tucson, Arizona • Sacramento, California • San Diego, California + 31 more

Conditions: Prostate Cancer
Interventions: ZD4054, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 896 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 19
States / cities: Tucson, Arizona • Greenbrae, California • Los Angeles, California + 16 more

Conditions: Diabetic Macular Edema
Interventions: Faricimab, Sham Procedure; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,479 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 119
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 105 more

Conditions: Acute Gout
Interventions: Canakinumab 150 mg, Triamcinolone acetonide 40 mg, Placebo to canakinumab, Placebo to triamcinolone acetonide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 96
States / cities: Anniston, Alabama • Birmingham, Alabama • Foley, Alabama + 81 more

Conditions: Overactive Bladder Syndrome
Interventions: Fesoterodine, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years and older · Male only
Enrollment: 947 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 62
States / cities: Birmingham, Alabama • Gilbert, Arizona • Litchfield Park, Arizona + 53 more

Conditions: High-risk Non-muscle Invasive Bladder Cancer
Interventions: Pembrolizumab, BCG; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2034
U.S. locations: 44
States / cities: Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 39 more

Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
Interventions: REGN5678, Cemiplimab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 24
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 17 more

Conditions: Coronary Artery Disease
Interventions: Early Bird® Bleed Monitoring System, Impella®; Device
Lead sponsor: Saranas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 11
States / cities: Phoenix, Arizona • Tucson, Arizona • Gary, Indiana + 7 more

Conditions: Epilepsy With Simple or Complex Partial Onset Seizures
Interventions: Eslicarbazepine acetate; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 103
States / cities: Birmingham, Alabama • Mobile, Alabama • Northport, Alabama + 82 more

Conditions: Leukemia
Interventions: filgrastim, sargramostim, cytarabine, daunorubicin hydrochloride; Biological · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 56 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 98
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more

Conditions: Graft Versus Host Disease
Interventions: Prochymal®, Placebo, Standard of Care for GVHD; Biological · Drug
Lead sponsor: Mesoblast, Inc.; Industry
Eligibility: 6 Months to 70 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 47
States / cities: Birmingham, Alabama • Tucson, Arizona • Duarte, California + 35 more

Conditions: Melanoma
Interventions: GSK1120212, Chemotherapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 13
States / cities: Tucson, Arizona • Fort Myers, Florida • Athens, Georgia + 10 more

Search by objective public record fields.

An Open-Label, Extension Study Evaluating the Safety, Toleration, and Efficacy of Sildenafil in Women With Sexual Arousal Disorder

A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases

Study of Kidney Tumors in Younger Patients

Diagnosis of Exercise-induced Bronchospasm (EIB) and Asthma in National Collegiate Athletic Association (NCAA) Division I Athletes

A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

Characterization of LV Strain Patterns in Mildly Elevated PCWP and PAH.

A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo

A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes.

Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial

Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.

Fesoterodine "add-on" Male Overactive Bladder Study

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Safe Surveillance of PCI Under Mechanical Circulatory Support With the Saranas Early Bird Bleed Monitoring System

Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs

S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia

Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma